Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Sanctura XR enters phase III program for overactive bladder

Sep. 13, 2005

Update on darifenacin in overactive bladder

Sep. 12, 2005

Anturol begins phase II study for overactive bladder syndrome

Sep. 12, 2005

Webcasts from ICS Annual Meeting now available

Sep. 8, 2005

A phase II study supports the use of fesoterodine in overactive bladder

Sep. 8, 2005

New therapeutic agents for renal diseases in early development at Astellas Pharma

Sep. 8, 2005

Update on the potential of SVT-40776 as a novel treatment for overactive bladder

Sep. 7, 2005

GABA-B receptor agonists prepared and tested at Bayer

Sep. 1, 2005

Bayer claims novel vanilloid VR1 receptor antagonists for urological disorders

Aug. 25, 2005

Darifenacin improves quality of life of patients with overactive bladder

Aug. 18, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...